arenapharm.com
http://www.arenapharm.com/pipeline.aspx
Arena Pharmaceuticals, Inc. You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites. 404 - Page Not Found. We're sorry, the Web address you entered is not a functioning page on our site. To return to the home page. If you feel something is missing that should be here, contact us. This page last updated: 05/20/2013. Additional Information regarding Arena is available in its SEC filings.
arenapharm.com
APD334 ‹ Arena Pharmaceuticals
http://www.arenapharm.com/apd334
Arena Pharmaceuticals, Inc. You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites. Drug Candidate for Treatment of Autoimmune Diseases. Etrasimod (APD334), an orally available S1P. Receptor modulator, discovered by Arena, has therapeutic potential in autoimmune diseases such as ulcerative colitis. S1P. Page for more information. Phase 2 Trial Ongoing. Etrasimod has not been approved by the US Food a...
arenapharm.com
GPCR FAQ ‹ Arena Pharmaceuticals
http://www.arenapharm.com/gpcr-faq
Arena Pharmaceuticals, Inc. You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites. Why are GPCRs important in human health? GPCRs play a crucial role in many diverse disease processes. The receptors have been linked to regulation of behavior and mood through GPCRs found in the brain, inflammation through receptors in the immune system, and metabolic processes, among others. What drugs target GPCRs?
arenapharm.com
GPCR Focus ‹ Arena Pharmaceuticals
http://www.arenapharm.com/gpcr-focus
Arena Pharmaceuticals, Inc. You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites. Our Drug Discovery Approach, Expertise and Technologies. We believe that our drug discovery approach, expertise and technologies offer several advantages for drug discovery, including:. Eliminating the need to identify the native ligand for an orphan receptor;. This page last updated: 5/20/2013.
arenapharm.com
Business Development ‹ Arena Pharmaceuticals
http://www.arenapharm.com/business-development
Arena Pharmaceuticals, Inc. You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites. BELVIQ (lorcaserin HCl) Marketing and Supply Agreements. BELVIQ is approved by the US Food and Drug Administration and will be available in the US only after its Schedule IV designation is effective on June 7, 2013. Temanogrel Co-Development and License Agreement. This page last updated: 11/20/2015. All images are own...
arenapharm.com
Career Opportunities - Arena GmbH ‹ Arena Pharmaceuticals
http://www.arenapharm.com/career-opportunities-arena-gmbh
Arena Pharmaceuticals, Inc. You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites. Arena Pharmaceuticals, Inc. Arena Pharmaceuticals, Inc. All offers of employment are subject to successful completion of a background verification. Sorry, there are no positions available through our website at this time. This page last updated: 5/20/2013.
arenapharm.com
Lorcaserin Lifecycle Management ‹ Arena Pharmaceuticals
http://www.arenapharm.com/lorcaserinLM
Arena Pharmaceuticals, Inc. You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites. Extended Release and CVOT. We and Eisai have prioritized the development areas of a once-daily formulation of lorcaserin, and evaluating, including as part of the FDA-required cardiovascular outcomes trial, or CVOT, lorcaserin’s impact on cardiovascular outcomes and effect on conversion to type 2 diabetes.
arenapharm.com
Executive Officers ‹ Arena Pharmaceuticals
http://www.arenapharm.com/executive-officers
Arena Pharmaceuticals, Inc. You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites. Director, President and Chief Executive Officer. Craig M. Audet, Ph.D. Senior Vice President, Operations and Head of Global Regulatory Affairs. Executive Vice President and Chief Business Officer. Dominic P. Behan, Ph.D., D.Sc. Director, Co-Founder, Executive Vice President and Chief Scientific Officer.
arenapharm.com
APD371 ‹ Arena Pharmaceuticals
http://www.arenapharm.com/apd371
Arena Pharmaceuticals, Inc. You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites. Drug Candidate for Treatment of Pain. We have completed a randomized, double-blind and placebo-controlled Phase 1b clinical trial to evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD371. Phase 1 Program Completed. This page last updated: 5/10/2016.